Every GLP-1 and muscle study from August 2026, synthesized into one cited review

What is inside

• Protecting Musculoskeletal Development and Physical Function in Adolescents on GLP-1 Therapy. (Childhood obesity (Print) · 2026-08-03 · Smith WA et al.)
• Defining Healthy Weight Loss and Target Weight in the Era of Highly Effective Treatment of Patients With Obesity. (Journal of cachexia, sarcopenia and muscle · 2026-01-01 · Bosy-Westphal A et al.)
• Comparative Effects of Individual Glucagon-Like Peptide-1 Receptor Agonist-Based Medications on Direct Measurement of Body Composition Among Adults With Overweight or Obesity With or Without Type 2 Diabetes: A Systematic Review and Network Meta-Analysis of Randomised Controlled Trials. (Diabetes, obesity & metabolism · 2026-05-28 · Wachiraphansakul N et al.)
• Turning obesity into an iatrogenic disease? (Clinical nutrition ESPEN · 2026-05-13 · Quilliot D)
• Dynamics of Body Composition and Metabolic Risk in Adolescents With Obesity Under GLP-1 Receptor Agonist Therapy. (Acta paediatrica (Oslo, Norway : 1992) · 2026-04-20 · Lopez A et al.)
• Targeting the activin/myostatin - actrii pathway to preserve skeletal muscle mass in obesity: mechanistic insights and therapeutic perspectives. (Reviews in endocrine & metabolic disorders · 2026-04-09 · Lisco G et al.)
• Adverse Events Associated with Incretin-Based Therapies: A Narrative Review on Mechanisms, Clinical Management, and Risk Mitigation. (Drug design, development and therapy · 2026-07-29 · Tobaiqy M, Alqutub ST)
• Low-Dose Tirzepatide for Obesity: Comparative Efficacy of 2.5 mg Versus 5 mg in Non-Diabetic Japanese Adults. (Diabetes, obesity & metabolism · 2026-07-28 · Amioka M et al.)
• Reappraisal of GLP-1 receptor agonists in older adults. (Trends in endocrinology and metabolism: TEM · 2026-08-07 · Maltese G, Koufakis T, Popovic DS)
• Muscle Health in the Era of Incretin-Based Weight Loss: Implications for Patients with Cardiovascular-Kidney-Metabolic Syndrome. (Cardiorenal medicine · 2026-08-06 · Nobakht N et al.)
• Protecting Musculoskeletal Development and Physical Function in Adolescents on GLP-1 Therapy. (Childhood obesity (Print) · 2026-08-03 · Smith WA et al.)
• Integrating GLP-1 Receptor Agonists Into Dermatology Practice: Safety and Monitoring Strategies. (Clinics in dermatology · 2026-08-06 · Narla S, Narla RR)
• Cross-Sectional Survey Results of Registered Dietitians of the Weight Management and Diabetes Dietetic Practice Groups of the Academy, Providing Medical Nutrition Therapy to People Using Glucagon-like Peptide-1 Receptor Agonist-Based Therapy. (Journal of the Academy of Nutrition and Dietetics · 2026-08-05 · Cardamone K et al.)
• Neuro-Adverse Events Associated with GLP-1 Receptor Agonists: A Study Based on the FAERS Database and External Validation Using NHANES Database (Preprint · 2026-08-06 · Bai L, Liu Y, Tongye H.)
• Identification and management of sarcopenia in patients with multimorbidity: An EFIM critically appraised and adapted guideline. (European journal of internal medicine · 2026-08-13 · Bernabeu-Wittel M et al.)
• Semaglutide-induced loss of skeletal muscle mass is blunted by co-administration of ketone esters. (JCI insight · 2026-06-09 · Abuetabh Y et al.)
• Cardiac safety of chronic inhibition of the myostatin-activin pathway with bimagrumab in healthy older adults. (The Journal of clinical endocrinology and metabolism · 2026-01-01 · Rooks D et al.)
• High animal protein and high plant protein meals differentially alter postprandial plasma amino acid concentrations but not glucose homeostasis in people with overweight/obesity in a randomized, cross-over, single-meal study. (The American journal of clinical nutrition · 2026-08-10 · Fappi A et al.)
• Imaging-Derived Sarcopenic Obesity and Cardiovascular Outcomes: Insights Into Heart Failure Risk and Muscle Biology. (Journal of the American College of Cardiology · 2026-07-01 · Sanghvi MM et al.)
• Risk of protein intake deficiency during treatment with GLP-1 and GIP/GLP-1 receptor agonists: considerations for secondary sarcopenia. (Advances in therapy · 2026-08-22 · Prokopidis K et al.)
• Body Composition Remodelling During GLP-1-Based Therapy: A Systematic Review and Meta-Analysis Using a Hierarchical Physiological Framework. (Diabetes, obesity & metabolism · 2026-08-17 · Lopes Menezes ML et al.)
• A multi-functional oral small molecule targeting energy and lipid metabolism to treat obesity and related metabolic disorders. (Science advances · 2026-08-21 · Lee JY et al.)
• Beyond weight: a stigma-free, integrated approach to obesity in patients affected by cancer. (Reviews in endocrine & metabolic disorders · 2026-08-18 · Watanabe M et al.)
• Incretin-based therapies in peri- and postmenopausal women with obesity: an expert position statement from the Spanish Menopause Society. (Maturitas · 2026-08-25 · Sánchez-Prieto M et al.)
• Longitudinal Changes in Body Composition, Adaptive Thermogenesis and Muscle Strength in Patients with Obesity Treated with Semaglutide. (Obesity facts · 2026-08-25 · Filippi-Arriaga F et al.)
• Emerging Myostatin and Metabolic Hormone Pathway Modulators in Cardiometabolic Disease: Mechanisms, Evidence, and Therapeutic Potential. (Journal of cardiovascular translational research · 2026-08-27 · Ahad A et al.)
• The Effects of Glucagon-Like Peptide-1 Receptor Agonists on Chemosensory Function and Ingestive Behavior. (Physiology & behavior · 2026-08-25 · Rutigliani G, Mattes RD)
• The effect of sex and endurance exercise training on the incretin signaling pathway in 17 rat tissues. (Physiological genomics · 2026-08-24 · Jin C et al.)

Every finding in this review is attributed to a specific study named in the guide, drawn from that month's research roundups. Where the evidence is a preprint, mixed, or thin, the guide says so instead of rounding up.